News articles about Genomic Health (NASDAQ:GHDX) have trended somewhat positive on Tuesday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genomic Health earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.6930667122946 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

GHDX has been the subject of several research reports. Cowen Inc reaffirmed a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Jefferies Group LLC reaffirmed a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research note on Friday, October 20th. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. ValuEngine cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $39.00 price target on shares of Genomic Health in a research note on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $32.67.

Genomic Health (GHDX) opened at $29.16 on Tuesday. Genomic Health has a 52 week low of $26.37 and a 52 week high of $34.02.

In related news, insider James J. Vaughn sold 1,379 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $31.86, for a total transaction of $159,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 21,379 shares of company stock valued at $676,131 over the last ninety days. Company insiders own 46.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Genomic Health (GHDX) Share Price” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/28/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-genomic-health-ghdx-share-price.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.